Answers are grounded in this paper and cite their sources.
Review article discusses advancements in managing type 1 diabetes mellitus and highlights new therapeutics.
Despite pharmacotherapeutic advancements in the management of type 1 diabetes mellitus during the past several decades, patients struggle to achieve glycemic goals. Additionally, hypoglycemia, especially in extremes of age, decreases quality of life. The lack of optimal glycemic control and risk for hypoglycemia are multifactorial. Nevertheless, endeavors aiming to develop pharmacotherapeutic options with enhanced pharmacokinetic, pharmacodynamic, and clinical profiles continue. This review article discusses recent ventures in 3 categories of insulin, non-insulin, and glucagon products.
No takes yet. Share an insight, caveat, or question.
Sabet et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: